Fang Yixuan, Zou Xinru, Hu Shuning, Ji Lili
Department of Pathological Anatomy, School of Medicine, Nantong University, Nantong 226001, China.
Zhongguo Fei Ai Za Zhi. 2022 Oct 20;25(10):735-741. doi: 10.3779/j.issn.1009-3419.2022.102.37. Epub 2022 Sep 28.
The morbidity and mortality of lung cancer ranks among the top cancers in the world. Non-small cell lung cancer (NSCLC) is the main pathological type of lung cancer, with limited treatment options and poor prognosis. The nuclear factor E2-related factor 2 (NRF2) signaling pathway is highly mutated and activated in NSCLC, and promotes the malignant progression of lung cancer through various mechanisms. NRF2-targeted therapy will provide new treatment strategies for patients with NSCLC. This article will review the basic structure and response pathways of the NRF2 pathway, the mechanism of NRF2 regulating lung cancer cell proliferation, and the research and development progress of NRF2 inhibitors. .
肺癌的发病率和死亡率在全球癌症中位居前列。非小细胞肺癌(NSCLC)是肺癌的主要病理类型,治疗选择有限且预后较差。核因子E2相关因子2(NRF2)信号通路在NSCLC中高度突变并激活,通过多种机制促进肺癌的恶性进展。靶向NRF2的治疗将为NSCLC患者提供新的治疗策略。本文将综述NRF2通路的基本结构和反应途径、NRF2调节肺癌细胞增殖的机制以及NRF2抑制剂的研发进展。